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Abstract 
Background: Seasonal malaria chemoprevention (SMC) is a strategy for malaria control recommended by the World 
Health Organization (WHO) since 2012 for Sahelian countries. The Mali National Malaria Control Programme adopted 
a plan for pilot implementation and nationwide scale-up by 2016. Given that SMC is a relatively new approach, there 
is an urgent need to assess the costs and cost effectiveness of SMC when implemented through the routine health 
system to inform decisions on resource allocation.
Methods: Cost data were collected from pilot implementation of SMC in Kita district, which targeted 77,497 children 
aged 3–59 months. Starting in August 2014, SMC was delivered by fixed point distribution in villages with the first 
dose observed each month. Treatment consisted of sulfadoxine-pyrimethamine and amodiaquine once a month for 
four consecutive months, or rounds. Economic and financial costs were collected from the provider perspective using 
an ingredients approach. Effectiveness estimates were based upon a published mathematical transmission model 
calibrated to local epidemiology, rainfall patterns and scale-up of interventions. Incremental cost effectiveness ratios 
were calculated for the cost per malaria episode averted, cost per disability adjusted life years (DALYs) averted, and 
cost per death averted.
Results: The total economic cost of the intervention in the district of Kita was US $357,494. Drug costs and person-
nel costs accounted for 34% and 31%, respectively. Incentives (payment other than salary for efforts beyond routine 
activities) accounted for 25% of total implementation costs. Average financial and economic unit costs per child 
per round were US $0.73 and US $0.86, respectively; total annual financial and economic costs per child receiving 
SMC were US $2.92 and US $3.43, respectively. Accounting for coverage, the economic cost per child fully adherent 
(receiving all four rounds) was US $6.38 and US $4.69, if weighted highly adherent, (receiving 3 or 4 rounds of SMC). 
When costs were combined with modelled effects, the economic cost per malaria episode averted in children was US 
$4.26 (uncertainty bound 2.83–7.17), US $144 (135–153) per DALY averted and US $ 14,503 (13,604–15,402) per death 
averted.
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Background
After an unprecedented period of success, with sub-
stantial investment in malaria control and reductions in 
malaria episodes, the progress has stalled [1]. In 2018, 
there were an estimated 228 million cases and 405,000 
related deaths worldwide, with a high proportion of these 
deaths occurring in sub-Saharan Africa (93%) mostly in 
children under 5 years [1].
In addition to the human morbidity and mortality 
impact, malaria places economic burdens on individu-
als, health systems and national governments. In Mali, 
malaria is the main cause of outpatient visits, hospitaliza-
tions and mortality in health facilities; children under five 
and pregnant women are the most affected [2]. Accord-
ing to a national survey in 2013, the prevalence of malaria 
parasitaemia by microscopy was 52% in children under 
5 years overall in Mali and 37% in the southern region of 
Kayes, the setting of this study [3]. In 2014, health facili-
ties across Mali registered more than two and half mil-
lion cases of suspected malaria, of which 1.7 million were 
clinical cases, 800,000 severe cases and 2309 deaths [4].
Seasonal malaria chemoprevention (SMC) was recom-
mended by the World Health Organization (WHO) in 
areas of highly seasonal malaria transmission across the 
Sahel sub-region in 2012. It consists of the administration 
of a complete treatment course of sulfadoxine-pyrimeth-
amine and amodiaquine (SP + AQ) at monthly inter-
vals to children aged 3 to 59  months, beginning before 
the start of the transmission season, with up to a maxi-
mum of four doses during transmission season [5]. The 
National Malaria Control Programme (NMCP) in Mali 
was one of the early adopters and introduced SMC in 
2012 with pilot implementation in one district and pro-
gressive expansion to other districts.
Few studies have assessed the cost and cost-effec-
tiveness of SMC introduction and distribution at scale 
through the routine health system. In addition, little is 
known about the detailed cost breakdown of SMC when 
implemented using fixed point distribution method [6, 
7]. Peer-reviewed cost and cost-effectiveness studies 
using data collected alongside clinical trials and model-
ling efforts have suggested that SMC is a low cost and 
highly effective intervention (Table 1). The lowest cost 
per child per dose reported was in Senegal at $1.96 for 
3 doses (inflated to 2016 USD) [7] and the highest cost 
per dose at $ 22.81 in the upper west region in Ghana 
(inflated to USD 2016) [6]. Cost drivers included the 
cost of the drugs, scale of the study, the delivery mode 
(fixed point vs. door-to-door), personnel costs (salaries) 
and incentives. Incentives reflect a payment (either in 
kind or in monetary terms) to an individual independ-
ent of any salary they may receive, for efforts carried 
out in addition to their routine activities.
There have been two implementation studies of SMC 
in Mali [8, 9]. In 2012, an evaluation of SMC was under-
taken by “Médecins Sans Frontières” (MSF) in Koutiala, 
the first Malian health district to implement SMC. 
Using budgetary estimates, the average cost of provid-
ing SMC to a child was estimated at $1.30 per child per 
round [8]. In addition, Mali was part of a large multi-
county rapid expansion of seasonal malaria chemopre-
vention in the Sahel (ACCESS SMC) implementation 
study [10]. Preliminary ACCESS SMC cost estimates 
suggested that the recurrent costs of delivering 4 doses 
of SMC to a child in Mali was $4.05 (2015 USD) [11]. In 
a later publication, an average economic cost for four 
treatments per child, across all seven ACCESS coun-
tries, of US $ 3.63 (US $ 2.71 to US $ 8.20) was obtained 
[12]. To date, this is the first study to use primary cost 
data to estimate the cost per disability-adjusted life year 
(DALY) averted for SMC.
SMC is a relatively new approach compared to other 
malaria control tools. Therefore, rigorous evaluations 
of the strategy when implemented through a routine 
health system, outside the context of clinical trials, are 
needed to inform resource allocation decisions. Often 
trials are well funded and able to incentivize those 
involved in ensuring the delivery of SMC, both in terms 
of financial payments and non-financial incentives such 
as additional training and improved access to drugs and 
other resources. The aim of this evaluation was three-
fold: firstly, to assess the district-wide primary cost data 
associated with the implementation of SMC in Kita as 
part of routine care; secondly to combine these costs 
with coverage levels identified in the project to estimate 
the effectiveness of SMC in Kita based upon an estab-
lished dynamic malaria transmission model. Thirdly, to 
use the costs and the effectiveness estimates to calcu-
late the incremental cost-effectiveness of the interven-
tion compared to no intervention.
Conclusions: When implemented at fixed point distribution through the routine health system in Mali, SMC was 
highly cost-effective. As in previous SMC implementation studies, financial incentives were a large cost component.
Keywords: Malaria, Mali, Seasonal malaria chemoprevention, Cost, Cost-effectiveness, Economic, Financial, Disability-
adjusted life year (DALY)







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 4 of 14Diawara et al. Malar J          (2021) 20:128 
Methods
Study site and population
Kita district, where SMC was implemented and evaluated 
in 2014, is located in the western region of Kayes, about 
180 kms north of Bamako, the capital city of Mali. Kita 
was one of the 21 districts in Mali to roll out SMC in 2014 
as part of the progressive national scale up of SMC. Kita 
has one district hospital, 40 community health centres, 
and 72 community health workers (CHWs). The popula-
tion was estimated to be 516,649 in 2014 with approxi-
mately 77,497 children between 3 and 59 months of age 
and parasitaemia prevalence for the region in 2013 was 
37% [13, 14]. SMC was implemented in all 336 villages/
quartiers and while approximately 77,497 children were 
forecast to receive SMC, an estimated 104,255 children 
actually received the intervention. This higher number 
of children than expected is explained by three factors. 
Firstly, some children older than 5 years are likely to have 
received the intervention; secondly, Bafoulabe, the dis-
trict next to Kita did not receive SMC and it is likely that 
children came from bordering villages to receive SMC; 
and finally, the study site covered a large agricultural 
area that, at the time of SMC administration, might have 
experienced a population swell given it was growing sea-
son so there was a need for increased labour.
SMC delivery and administration
SMC delivery refers to the process of obtaining the 
resources (mainly drugs and incentives) from the central 
stores to the end user (in this case the child). In the con-
text of this study, incentives capture the financial com-
pensation for supporting for SMC implementation in 
Kita. SMC administration (sometimes referred to in pre-
vious SMC costing papers as distribution) refers to the 
activities associated with giving the drugs to the child on 
the day(s) of SMC.
In Kita, the SMC campaign was organized in 2014 
using a fixed point distribution method. Specifically, drug 
distribution was channelled through the district hospital 
and community health centres, and SMC was delivered at 
village focal points. Distribution was the responsibility of 
government employed health staff, primarily nurses and 
community health workers (CHWs).
Children aged 3–59  months received sulfadoxine-
pyrimethamine and amodiaquine (SP + AQ) at monthly 
intervals over the four months of August, September, 
October, and November 2014. Before drug distribution 
started, several meetings were held from May to August 
2014 at the national, regional, district and sub-districts 
levels in Kita in preparation for SMC implementation. 
Two technical groups composed of 8 staff members 
from NMCP and implementing partners were created: 
one to establish, review and update the SMC distribu-
tion modules, and develop data collection tools; and 
the second group to develop a communication plan for 
SMC implementation. SMC dispensers, who were CHWs 
and nurses, received a two-day training course on SMC 
administration using the training modules developed. 
Normally, the Central Pharmacy (Pharmacie Populaire 
du Mali, PPM) provides drugs and medical supplies to 
the Regional Health Directorate in Kayes. The Regional 
Directorate then provides supplies and drugs to health 
districts who dispatch them to the district and Commu-
nity Health Centres. However, because of a delay in pre-
paring for implementation, on this occasion SMC drugs 
were paid for by the Ministry of Health (MoH) through 
the NMCP and delivered directly to the district heath 
centre of Kita by the PPM without passing through the 
Regional Health Directorate. It then took five days for the 
district health centre to deliver the drugs and supplies to 
community health centres.
The SP + AQ used for SMC in Kita were not co-
blistered or pre-packed conditional on age group. The 
drugs, therefore, had to be cut and repacked by the dis-
trict health team. For this, 10 persons were recruited and 
worked on the drugs packaging for 25  days. After the 
drugs were packaged, an allocation plan was developed 
to distribute the SMC drugs and necessary supplies for 
implementation to the community health centres and 
villages heath workers. Information, sensitization and 
communication messages on SMC were developed and 
delivered through the two most popular local radio chan-
nels for six months (July to December 2014). Additional 
specific messages were developed and added during the 
distribution period. In addition, at the community level, 
mobilization and sensitization activities were carried out.
SMC drug administration was performed by Kita dis-
trict health staff and comprised 588 drug dispensers 
(nurses and CHWs) organized into 133 teams of 2–6 
health workers each at health centres (n = 37 teams) and 
village fixed points (n = 96 teams). The first dose of AQ 
and the single dose of SP was given the first day by health 
workers. Children were observed for 30  min, and if the 
child vomited within this time, another dose was admin-
istered. The second and third doses of AQ were given to 
parents to be administrated at home. Further details are 
provided elsewhere [3].
All labour used in SMC distribution was employed 
and paid by the MoH, except implementing partner 
staff who were paid by the non-government organiza-
tion Save the Children [12]. Supervision and monitoring 
were performed during the distribution period by teams 
composed of staff at national level ((NMCP, Maternal 
and Child Survival Programme, and National Federation 
for Community Health Centres Association)), regional 
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level and district level. As with all SMC programmes, 
incentives were given to all of those involved: NMCP 
personnel, Fédération Nationale des Associations Com-
munautaires, staff from the district hospital and com-
munity health centres, CHWs and drivers. Incentives 
(per-diems and accommodation where required) varied 
according to categories of the staff and location (local, 
district level, regional). In Kita incentives were set at daily 
rates comparable to financial incentives paid for deliver-
ing other interventions and research studies conducted 
in the area previously. The daily incentive for a rural 
doctor was comparable to their daily salary, and a little 
less than a CHW could expect to receive for their daily 
duties. On average those involved in the implementation 
were paid approximately 36 days of incentives for helping 
with SMC implementation in 2014.
Costing
Costs are presented from the provider perspective using 
an ingredients approach whereby the relevant resources 
were identified and measured at the time of the SMC 
implementation to estimate the total cost of the interven-
tion [5]. The choice of provider perspective was based on 
data availability and the intention of the study to inform 
decision makers how much the intervention would cost 
for funding proposes. Both financial and economic costs 
(recurrent and capital) are estimated for the 4 rounds of 
distribution. Financial costs reflect the actual expenditure 
required to deliver the intervention such as the cost of 
drugs and incentives. Economic costs capture the oppor-
tunity cost of all resources used to provide SMC, whether 
or not they incur a financial cost. For example, the time 
of health personnel involved in SMC delivery represents 
an economic cost as the staff already received a salary 
so there was no additional financial commitment, how-
ever they could have spent their time on other activities, 
so we need to capture the opportunity cost [6, 15]. Only 
2014 cost data were used in this study and are presented 
in 2016 Communauté Financière en Afrique (CFA) and 
US dollars (USD). A conversion rate of CFA 494.17: USD 
1 was assumed based on the average of August 2014 
inflated to 2016 using US Inflation Calculator [16].
Table 2 presents the cost categories used in the analy-
sis: planning, communication, training, drugs, personnel, 
equipment and transport. In addition to the total imple-
mentation cost and the total cost per round, unit costs 
Table 2 Cost categories
NMCP National Malaria Control Program, MCSP/SC Maternal and Child Survival Program
Cost category
Input or Activity
Description Sample size Data source
Planning meetings: In total six meetings were held, including five field visits 6 meetings MCSP expenses record
Training A group of trainers was trained on SMC distribution. In turn, 
community health center staff, community and voluntary 
health workers (n = 100) were trained by trainers (n = 9). 
Total training cost was estimated using the number of 
participants and daily per diems; accommodation, refresh-
ments and transportation costs were also included
6 trainings MCSP expenses record
Drugs Quantities were estimated by age group from NMCP 2014 
drug accountability plan
Number of drugs received is from the drug accountability 
plan
AQ: 179,627 
packs of 6 
tablets
SP: 359 boxes 
of 1000 
tablets
Costs were collected from Pharmacie Populaire 
du Mali drug stock inventory state, ACT, RDT, 
and anti- malarial store in November 2014
Personnel Personnel costs were collected and calculated in planning, 
training and distribution categories and captured both 
those directly responsible for delivering SMC and those 
supervising. Staff costs were classified by specialty; salary 
(plus associated benefits such as pensions, housing allow-
ance etc.) Per diems and incentives were calculated accord-
ing to activity
588 Ministry of Health personnel pay slips for 2014
Equipment The costs of materials and equipment such as drinking 
glasses, buckets, chairs and tables used during dispensing 
SMC
MCSP expenses record
Transport For transport cost during meetings, trainings and drugs 
distribution, MCSP/SC vehicles were used as well as rented 
vehicles. Vehicles maintenance costs were included in rent-
ing costs
The total number of vehicles used and the costs 
were estimated from vehicle renting cost per 
day from the Ministry of Health vehicle renting 
documents
Fuel costs were extracted from MCSP/SC 
monthly activities accounts
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are estimated in terms of cost per child fully adherent (i.e. 
a child that had the first of each of the SMC drugs under 
observation in all 4 rounds) and cost per child partially 
covered (i.e. a child that had the first SMC drugs under 
observation in 1, 2 or 3 rounds). Fully adherent is defined 
as child who received all 4 rounds and highly adherent as 
child who received at least 3 rounds.
Effectiveness
An aim of this district-wide SMC delivery was to see how 
feasible the intervention was at scale outside of trial con-
ditions. The project focused on coverage and collected 
limited data on health outcomes (specifically prevalence 
of malaria and anaemia) [13]. Instead, modelling was 
used to provide an indication of the likely effectiveness 
of the intervention in Kita. An established dynamical 
transmission model was used [17]; this model has previ-
ously been used for a range of applications including to 
establish global investment targets for the WHO Global 
Technical Strategy [18]. Full details, as well as source 
code and instructions for compilation and running, of 
the model are available elsewhere [19, 20]. In brief, the 
model is individual-based and non-spatial, with rainfall 
driving seasonal patterns of mosquito emergence and 
subsequent patterns of the entomological inoculation 
rate, incidence of malaria and prevalence of infection, 
which then determine the level of onwards transmis-
sibility to the mosquito. The human component of the 
model incorporates heterogeneity in exposure and both 
acquired and age-dependent immunity, which affects (i) 
the probability of developing severe and clinical disease, 
(ii) the duration of detectable blood-stage infection and 
(iii) onwards infectivity to the mosquito. This allows the 
model to capture the relationship between transmis-
sion and age-dependent patterns of prevalence and dis-
ease across a wide range of settings and to simulate the 
onwards impact of multiple interventions upon trans-
mission (though the magnitude of this impact within the 
model is limited when SMC is only provided to under 5 s 
[21]. The model has also been shown to replicate seasonal 
patterns of malaria burden, driven by rainfall [22] and 
the effectiveness of SMC within trials (Cairns et al., pers. 
commun.), to a high degree of accuracy. Here the model 
was calibrated to patterns of seasonality, based upon 
rainfall gauge data between 2002 and 2008 in the region, 
smoothed by Fourier transformation, to provide typi-
cal patterns of rainfall throughout the year. Long-lasting 
insecticidal nets (LLIN) use within the area was also cap-
tured by the model, assuming a linear increase from 0% 
in 2000 to 56.9% observed in Kayes region in 2013 [3] 
which had risen to 65.2% in 2015 [2] following the uni-
versal coverage campaign in 2014. Usage immediately 
following the 2014 campaign (which was not measured) 
was calibrated to achieve 65% usage in the area at the 
end of 2015 (when the above survey was done), with no 
further assumed distribution in 2015–2017. The model 
assumes a constant per-capita rate of attrition in usage in 
the absence of receiving a new net of 0.2 per year [23]. 
Simulations were then conducted using 1000 parameter 
sets representing separate draws from the joint posterior 
distribution of the underlying transmission model. Base-
line vectorial capacity in each simulation was calibrated 
to 2014 dry-season prevalence according to a triangle dis-
tribution with mode of 24.1% and a 95% interval between 
20.7% and 27.8%, based upon the mean and binomially-
distributed 95% confidence intervals (CIs) observed in 
this survey, and further accounting for temporal trends in 
seasonality, LLIN usage and insecticidal coverage.
Four rounds of SMC with SP + AQ were simulated, 
with a duration of prophylaxis following a Weibull dis-
tribution with scale parameter 38.1 and shape parameter 
4.3 fitted to published point estimates of the protective 
efficacy over time from a trial in Burkina Faso [20] (see 
Fig.  1). This profile provides strong protection for the 
first 3–4 weeks after a round, declining to 50% protection 
around 5 weeks, and then subsequently declining rapidly. 
The model was calibrated to match the per-capita num-
ber of doses delivered during the intervention by setting 
the coverage of the intervention within the model to the 
overall probability of receiving a dose in any given round 
according to interviews with the caregivers of children 
who reported receiving the intervention in 3396 of 4505 
(75.3%) potential per-protocol rounds within the survey 
Fig. 1 Figure shows the estimated protective efficacy from time 
since receiving a round of SMC as estimated in [reference 24] 
compared to the profile used within the model
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[13]. Uncertainty in the timing of these doses was then 
captured by varying the timing of the intervention rela-
tive to the seasonal peak by summarising simulations 
using 1000 draws from a triangle distribution with mode 
centred around the seasonal peak in transmission, with 
extremes between a month before and after this optimal 
scheduling.
Goodness-of-fit was assessed by comparing the model 
prevalence to prevalence survey collected at the end of 
2012 [3] and a month after the final round of SMC [13]. 
Burden outputs considered were uncomplicated clinical 
malaria and severe malaria in children under five years 
and in the wider population, with estimates of lives saved 
based upon a case-fatality rate of 0.3% [24] per malaria 
case. The modelling incorporated the universal LLIN 
campaign within the area in 2014; as a result, in addi-
tion to our estimates of 2014 impact, were present both 
the estimates of the impact of SMC in 2014 specifically, 
and estimates if SMC at the same coverage as in 2014 had 
been extended across the 3-year LLIN distribution cycle, 
in order to provide a measure of the likely effectiveness of 
SMC if applied continuously in the area.
Incremental cost effectiveness analysis
An incremental cost effectiveness ratio (ICER) was calcu-
lated by dividing the annual total economic cost of SMC 
by the annual modelled estimates of (1) the number of 
uncomplicated and severe malaria cases averted, (2) the 
DALYs averted, and (3) the deaths averted. The annual 
number of episodes averted was an average of a three-
year cycle where the effects of LLINs were also included. 
DALYs are a measure of burden of disease and can be 
used as a summary measure to determine and compare 
the cost-effectiveness of different types of interventions 
across different diseases and settings [25, 26]. They allow 
for a more informed assessment of cost effectiveness in 
relation to thresholds and acceptability. There is no gold-
standard for when an intervention is deemed cost-effec-
tive. Indeed, the use and mis-use of thresholds is much 
debated [27, 28]. In helping interpret whether SMC was 
cost effective we present our findings using two very con-
servative thresholds: (i) US $780.51, Mali’s 2016 Gross 
Domestic Product (GDP) per capita and (ii) an even more 
stringent World Bank threshold of US $250 per DALY 
averted [29, 30].
Ethical considerations
The study protocol was reviewed and approved by the 
Ethical Committee of the Faculty of Medicine, Pharmacy 
and Dentistry of the University of Bamako prior to the 




The total financial cost to dispense SMC to the 104,255 
children in Kita was US $316,111 and the total economic 
cost was US $357,494. The main economic costs by input 
were drugs (34%) and personnel (31%). The bulk of per-
sonnel costs were due to $81,455 spent on incentives 
(23% of the total economic costs) (Table  3). The most 
costly activity was the end stage, dispensing the drugs to 
the children (Table 4). Financial and economic cost were 
similar, the main difference being the already covered sal-
ary costs of facility-based health staff that were included 
in economic costs.
The average financial unit costs per child per round was 
US $0.73. The economic costs by round of SMC and per 
child are shown in Table 5. The economic costs by round 
were similar for all the rounds except round 1, where 
the number of children reached was lower compared to 
the other rounds. On average, SMC cost $0.86 (424.986 
FCFA) per child/per round. Adding the averages across 
the four rounds gives a cost, on average, of $3.43 per child 
for the annual economic cost per child receiving SMC. 
However, this does not take into account adherence. In 
terms of how the costs changed relative to adherence, 
the cost of a fully adherent child having received all four 
rounds was US $6.38. (i.e. total economic costs divided by 
the 53.8% of 104,255 children estimated to have received 
at least the first day treatment of all four SMC rounds in 
the trial [13]) There is evidence to suggest that receiving 
even three rounds of SMC provides substantial protec-
tion [31, 32] which would make the cost per child highly 
adherent US $4.69.
Effectiveness
Figures  2, 3 shows the range of model simulations for 
transmission in Kita prior to SMC and during SMC 
Table 3 SMC implementation in  Kita: Total annual 
financial and economic costs by input of 2016 USD
a PPM Central Pharmacy/Pharmacie Populaire du Mali
b Information Education & Communication
Financial cost Economic cost
$ % $ %
Personnel 88,429 28 110,729 31
Drugs 122,060 39 122,060 34
Transport 36,190 11 36,190 10
IECb 6584 2 6584 2
Equipment 35,393 11 35,392 10
Other 27,454 9 46,538 13
Total 316,111 100 357,494 100
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implementation, as well as counter-factual simulations 
for the trajectory of transmission and patterns of bur-
den that would have occurred in the absence of SMC. 
Simulations were calibrated to the pre-intervention sur-
vey, LLIN scale-up and seasonal rainfall; show a good fit 
to prevalence measured soon after the end of the 2012 
transmission season; and are within the range of the 
prevalence observed soon after the end of the interven-
tion (Fig.  4). Counter-factual simulations capture the 
likely reductions in burden that will have occurred fol-
lowing the LLIN campaign in 2014, with transmission 
increasing towards the end of the 3-year LLIN distribu-
tion cycle. In the year of SMC implementation our simu-
lations are consistent with SMC preventing 660 (435–922 
95% uncertainty interval (UI)) uncomplicated cases and 
15.4 (8.42–24.3 95% UI) cases of severe malaria per 1000 
children reached among children below five years of age. 
In the all-age population, which also captures the impact 
of SMC on transmission, this represents 118 (78.2–163 
95% UI) cases and 2.61 (1.43–4.14 UI) severe cases per 
1000 person-years. Averaged over the 3-year LLIN distri-
bution cycle this gives 804 (478–1213 95% UI) uncompli-
cated cases and 16.5 (8.89–27.1 95% UI) cases of severe 
malaria per 1000 children reached and 141 (84.3–209 
95% UI) cases and 2.73 (1.46–4.43) severe cases per 
1000 person-years. Table 6 provides the number of cases 
averted annually incorporating population size and these 
figures inform the ICER.
ICER
The incremental cost effectiveness ratios (ICER) per 
malaria episode averted were estimated for children 
and for the entire population (Table  7). Based on pre-
dicted coverage, the financial cost per childhood episode 
averted was estimated at US $5.07 (uncertainty bounds 
3.36–8.53) and the economic cost was US $5.74 (3.80–
9.65), respectively. In the all-ages population in Kita, the 
economic cost per malaria episode averted was US $4.92 
(range 3.31–8.21). Given that coverage was higher than 
predicted, it could be argued that the more accurate 
ICERs are a financial cost per childhood episode averted 
of US $3.77 (uncertainty bounds 2.50–6.34) and an eco-
nomic cost of US $4.26 (range 2.83—7.17) per child-
hood episode averted. As shown in Table 7, the ICER is 
US $144 (135–153) per DALY averted and US $14,503 
(13,604–15,402) per death averted based on actual chil-
dren covered. See Appendix 1 for DALY calculations.
Discussion
The economic cost of SMC was US $0.86 per child per 
SMC round and the cost per child fully adherent was 
$6.38. The cost effectiveness ratios were estimated at an 
economic cost of US $4.26 per childhood episode averted 
and US $144 per DALY averted. Thus, SMC was cost 
effective as US $144 per DALY averted was well below 
two very conservative thresholds: (i) USD $779.94 per 
DALY averted, based on Mali’s 2016 GDP per capita [33] 
and (ii) an even more stringent World Bank threshold of 
$250 per DALY averted [29, 30].
In addition to the multi-country ACCESS SMC study 
(which included Mali) (12), other studies of routine SMC 
implementation comparable to Kita in terms of scale and 
their attempt to deliver through the routine health sys-
tem have been conducted in Senegal [7], Upper West 
Region of Ghana [6], Koutiala in Mali [8], and elsewhere 
(see Table 1). At US $0.86 per child per round, Kita SMC 
unit costs are amongst the lowest reported to date. Only 
Senegal, where the economic cost per child per round 
Table 4 SMC implementation in Kita: Total annual financial and economic costs by activity of (2016 USD)
a Information Education & Communication
Activity Financial cost Economic cost
CFA $ Percentage 
of total
CFA $ Percentage 
of total
Planning meetings 2,305,217 3006 1.39% 2,887,971 5,925 1.66%
SP-AQ Tablets 100,325 100,325
Drug Packing 5,823 5,823
PPM Feesa 17,632 17,632
Purchasing and preparing SMC drugs 59,495,789 122,060 35.91% 59,495,789 122,060 34.14%
Training 6,674,267 13,693 4.03% 8,093,772 16,605 4.64%
Equipment 17,251,396 35,393 10.41% 17,251,396 35,392 9.90%
Delivering to distribution point 374,863 626 0.23% 382,512 785 0.22%
Dispensing 74,073,986 134,752 44.71% 82,933,503 170,144 47.59%
IECa 3,209,310 6,584 1.94% 3,209,310 6,584 1.84%
Total 165,690,044 316,111 100% 174,254,252 357,494 100%
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was reported to be $0.55, shows a lower economic cost 
per round. A major difference in the Kita study and the 
Senegalese study is that costs incurred at national level 
were not included in the total Senegalese unit cost. Kita 
SMC delivery unit costs were lower than the two Malian 
SMC studies conducted to date. In Koutiala, an estimate 
based on the budget expenses found a unit cost per child 
per round at 1.12 euros or $1.30 (inflated to 2016 $US) 
[8], compared to an average economic cost of US $ 0.86 
per round in Kita. The other Malian study, ACCESS-
SMC, suggests a preliminary average estimates of $4.05 
(USD 2015) for the delivery of four doses using both 
door-to-door and fixed point delivery strategies [10, 11] 
compared to US $3.43 delivery of four rounds in Kita. 
The average cost of four treatments per child, weighted 
across the seven ACCESS countries was US $3.63 (12).
This study shows drug costs and personnel costs 
(largely made up of incentives) were the main cost driv-
ers. This is in line with most previous SMC cost studies, 
for example in the Senegal study incentives to CHWs 
and drugs costs were the highest costs, representing 
44% and 27% of the total cost, respectively. The eco-
nomic cost estimate of US $4.26 per malaria case averted 
(2.83–7.17), is lower than that found in Hohoe Ghana US 
$24.87 (22.63–27.36) per case averted and Upper West 
Region Ghana US $108.41 (101.01–123.01). However, the 
per death were higher than Upper West Region Ghana. 
At US $144 per DALY averted it is well below both con-
servative thresholds we enlisted to identify highly cost 
effective interventions. This is the first SMC cost-effec-
tiveness analysis to use primary cost data to estimate the 
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Fig. 3 Severe malaria incidence in children under 5 with SMC and no SMC in Kita district
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large-scale implementation studies to estimate the cost- 
effectiveness of SMC using a fixed point distribution.
The study has limitations. While the costs were taken 
directly from the intervention site, the effectiveness 
of the intervention was modelled on data drawn from 
surveys as data on malaria episodes and deaths averted 
were not available. However, the model was calibrated 
to local data and has been widely published. In terms of 
generalising beyond this study setting, SMC drugs were 
not in co- blister packs, so had to be packed manually and 
Fig. 4 Simulations of the effectiveness of SMC in Kita shows a simulations of the impact of SMC upon prevalence in ages 3 -59 months, with 
estimates from prevalence surveys, including the 2014 pre-intervention to which the simulations were calibrated are shown as green dots with bars 
showing binomial 95% confidence intervals, b simulated incidence of uncomplicated clinical malaria in children under 5 and c incidence of severe 
malaria in children under 5. In all plot simulations using model parameters from the median of the joint posterior distribution and modal values 
from the triangle-distributed uncertainty distributions are shown in dark lines (blue for simulations in the absence of SMC, salmon in the presence 
of SMC), shaded areas show 95% uncertainty intervals based upon the 1000 simulated parameter draws. * Note these are 1 year averages based on 
a 3 year cycle that takes into account the waning protective efficacy of LLINs
Table 6 Effectiveness outcomes: malaria episodes averted
a Uncertainty bound
Total over 1 year time  horizona Kita pop Children All population
Cases Uncomplicated Severe Cases Uncomplicated Severe
Mean 62,313 61,031 1282 72,676 71,265 1411
Lower 95%  limita (based on 1000 simulations) 37,047 36,358 689 43,535 42,781 754
Higher 95% limit (based on 1000 simulations) 94,004 91,904 2099 108,144 105,853 2291
Table 7 Cost effectiveness analysis of SMC (US $ 2016)
a Uncertainty bounds – for cost per episode these were taken from the ranges of the model effectiveness estimates. For the DALYs and Deaths a ± 20% was used in 
the absence of any cost uncertainty, a gamma distribution was assumed for all parameters and 10,000 iterations were run using monte carlo simulations
Mean Lower 95%  limita Higher 95% limit
Costs Per Episode Averted
 Financial cost per childhood episode averted (actual coverage) 3.77 2.50 6.34
 Economic cost per childhood episode averted (actual coverage) 4.26 2.83 7.17
 Financial cost per childhood episode averted (predicted coverage) 5.07 3.36 8.53
 Economic cost per childhood episode averted (predicted coverage) 5.74 3.80 9.65
 Financial cost per all ages episode averted (predicted coverage) 4.35 2.92 7.26
 Economic cost per all ages episode averted (predicted coverage) 4.92 3.31 8.21
Economic Cost per DALY averted (actual coverage) 144 135 153
Economic Cost per Death averted (actual coverage) 14,503 13,604 15,402
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this resulted in additional costs. Using co-blister drugs, 
depending on their price, might lead to an increase the 
cost of the intervention.
Conclusion
SMC was highly cost effective when delivered at large scale, 
fixed-points through the routine health system in Mali. The 
main costs were drugs and personnel, with financial incen-
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Appendix 1: DALY and deaths averted calculations
DALYs for a disease or health condition are calculated 
as the sum of the Years of Life Lost (YLL) due to prema-
ture mortality in the population and the Years Lost due to 
Disability (YLD) for people living with the health condi-
tion or its  consequences,12:
These calculations incorporate weights for life expec-
tancy, age, future time and disability. See the table below 
for the weightings assigned to our analysis.3
 where K: age weighting modulation factor, C: constant, 
r: discount rate expressed as decimal, a: age of onset dis-
ability, β: parameter from the age weighting function, L: 
duration of disability, D: disability weight.
Inputs







K 0 0 No age weighting 
applied
r 0.03 0.03 A discount rate of 
3% applied
a 2.5 2.5 Mid point between 
sample cohort 
of 0–5
B 0 0 No age weighting 
applied
LD (7 or 30 days) 0.019178082 0.082191781 The assumed dura-
tion of an uncom-
plicated malaria 
episodes was 
7 days, expressed 
in years (7/365) 
and a severe 
episode, 30 days, 
expressed in years 
(30/365)
DALY = YLL+ YLD.
Years of life lost (YLD)

















1 Devleesschauwer et al. [34].
2 Larson [35].
3 Fox-Rushby and Hanson [36].
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D 0.006 0.133 IHME, GBD 2016–
2017 (based on 
2015 estimates at 
the most recent 
weightings avail-
able)
Life expectancy 72 72 According to the 
Global Health 
Observatory 
72.0 years was 
the average life 
expectancy at 

















DALY per episode using the above parameters
 YLD 0.019 0.082
 YLL 30.31
The total number of DALYs was calculated by multiplying the DALYs weights 
with the annual sum of clinical and severe episodes predicted in the 
epidemiological model
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